CRM Slimming Down?

[anonymous]

Let’s be honest. There are too many cooks in the kitchen. 2 card reps per territory. 2 PCP reps per territory. ISS reps who are overpaid to stay home and send emails. Virtual reps who sit at home and collect paychecks. That isn’t even including management or the reimbursement team. Whose going to be cut first???

Let corporate keep feeding you the bs that we are “the right size” you all know how Pharma works. They will feed you the BS to keep you working until the day before you’re told to stay home to wait and see if you have a job.

To top it off, more than half of the “pips” are lies. Come on people! Get your heads out of the clouds!

 

[anonymous]

It’s obvious that there will be cuts in CRM. Senior management has been very quiet but we know better. Here are just a few obvious reasons why CRM will be impacted by the reorg:

1. CRM now called CV. Renal is gone which means we won’t be promoting iptacopan due to be approved in 2023

2. Entresto going generic 7/23 or early 2024

3. The lackluster Leqvio launch

4. Over-bloated sales force and you know who you are

Please feel free to add to the list!

 

[anonymous]

It’s obvious that there will be cuts in CRM. Senior management has been very quiet but we know better. Here are just a few obvious reasons why CRM will be impacted by the reorg:

1. CRM now called CV. Renal is gone which means we won’t be promoting iptacopan due to be approved in 2023

2. Entresto going generic 7/23 or early 2024

3. The lackluster Leqvio launch

4. Over-bloated sales force and you know who you are

Please feel free to add to the list!

Point number 3 is an understatement. This may be the worst launch in pharma history.

 

[anonymous]

It’s obvious that there will be cuts in CRM. Senior management has been very quiet but we know better. Here are just a few obvious reasons why CRM will be impacted by the reorg:

1. CRM now called CV. Renal is gone which means we won’t be promoting iptacopan due to be approved in 2023

2. Entresto going generic 7/23 or early 2024

3. The lackluster Leqvio launch

4. Over-bloated sales force and you know who you are

Please feel free to add to the list!

 

[anonymous]

Let’s be honest. There are too many cooks in the kitchen. 2 card reps per territory. 2 PCP reps per territory. ISS reps who are overpaid to stay home and send emails. Virtual reps who sit at home and collect paychecks. That isn’t even including management or the reimbursement team. Whose going to be cut first???

Let corporate keep feeding you the bs that we are “the right size” you all know how Pharma works. They will feed you the BS to keep you working until the day before you’re told to stay home to wait and see if you have a job.

To top it off, more than half of the “pips” are lies. Come on people! Get your heads out of the clouds!

You aren’t wrong, except the part you missed is that all these people overlap in large territories and the PCP and CSS reps are generating all the business. Of course they then have to fight for whose patients are whose. The number of people who make a lot more money than me, while never leaving home, is astounding. We could “right size” by working on a true specialty or buy and bill model, paid by zip codes, not specialties. Then we could all have smaller territories and more accountability.

 

[anonymous]

Let’s be honest. There are too many cooks in the kitchen. 2 card reps per territory. 2 PCP reps per territory. ISS reps who are overpaid to stay home and send emails. Virtual reps who sit at home and collect paychecks. That isn’t even including management or the reimbursement team. Whose going to be cut first???

Let corporate keep feeding you the bs that we are “the right size” you all know how Pharma works. They will feed you the BS to keep you working until the day before you’re told to stay home to wait and see if you have a job.

To top it off, more than half of the “pips” are lies. Come on people! Get your heads out of the clouds!

Who are you arguing with?
Do you think you're the only one who sees this?
It will be top-down (the ISET team is a complete tragedy and obviously unnecessary) but field sales will ultimately have cuts - probably not in '22 but surely in '23.

 

[anonymous]

It’s obvious that there will be cuts in CRM. Senior management has been very quiet but we know better. Here are just a few obvious reasons why CRM will be impacted by the reorg:

1. CRM now called CV. Renal is gone which means we won’t be promoting iptacopan due to be approved in 2023

2. Entresto going generic 7/23 or early 2024

3. The lackluster Leqvio launch

4. Over-bloated sales force and you know who you are

Please feel free to add to the list!

Not that it matters but the Glint results have been AWFUL! They should look at the managers but let’s be honest, they’ll cut the lower line people first.

I think I’m more annoyed by those that act like things are just fine. Sure keep production going until cuts, but it gets to a point where we all need to be realistic.

 

[anonymous]

Who are you arguing with?
Do you think you're the only one who sees this?
It will be top-down (the ISET team is a complete tragedy and obviously unnecessary) but field sales will ultimately have cuts - probably not in '22 but surely in '23.

Yep and leadership made it this way. Corporate allowed the sales team to become bloated. They’re still filling vacancies. Stop filling vacancies until this nonsense is over!!

 

[anonymous]

The disconnect here, especially in CRM, is beyond pathetic. Leqvio is a disaster, and it’s way past time for those in charge to take responsibility for this 9.7 billion dollar failed launch. Vas and company should be ashamed of themselves for how this was rolled out.

 

[anonymous]

The disconnect here, especially in CRM, is beyond pathetic. Leqvio is a disaster, and it’s way past time for those in charge to take responsibility for this 9.7 billion dollar failed launch. Vas and company should be ashamed of themselves for how this was rolled out.

But they won’t be. They’ll blame the sales force, even though we have told them from the beginning this stupid model won’t work. It’s a great product, we are getting in our own way.

 

[anonymous]

The disconnect here, especially in CRM, is beyond pathetic. Leqvio is a disaster, and it’s way past time for those in charge to take responsibility for this 9.7 billion dollar failed launch. Vas and company should be ashamed of themselves for how this was rolled out.

ashamed is right! They had years to get this delayed launch right!!! Pathetic leadership!!!

 

[anonymous]

But they won’t be. They’ll blame the sales force, even though we have told them from the beginning this stupid

Let them blame the sales force all they want and pass the buck. Which is pretty much what all of these idiots do to cover their ass for the massive mistakes that they’ve made. This launch has been nothing short of disgraceful. Obviously senior management refuses to accept the fact that their strategy has failed. CRM needs a fresh start with competent people at the top who actually know what they’re doing.

 

[anonymous]

ashamed is right! They had years to get this delayed launch right!!! Pathetic leadership!!!

Land of misfit Leaders. They aren’t leaders— bunch of idiots.

 

[anonymous]

Land of misfit Leaders. They aren’t leaders— bunch of idiots.

When they judge you, yawn.
When they misunderstand you, smile.
When they underestimate you, laugh.
When they condemn you, ignore.
When they envy you, rejoice.
When they oppose you, prevail.

 

[anonymous]

Too many layers of uselessness in a business environment that continues to keep pharma out. In New England, you could have 1 Novartian per state and accomplish the same as 10 people. Yes, it’s that bad!!

 

[anonymous]

Too many layers of uselessness in a business environment that continues to keep pharma out. In New England, you could have 1 Novartian per state and accomplish the same as 10 people. Yes, it’s that bad!!

It’s not just New England. New Mexico, New Hampshire, New York, New Jersey and the rest of America is the same!

 

[anonymous]

Serious question - what is the value in having abl, soc, Adsar & iss?

 

[anonymous]

But they won’t be. They’ll blame the sales force, even though we have told them from the beginning this stupid model won’t work. It’s a great product, we are getting in our own way.

Novartis, we would never get in our own way. Ever. hahaha.

 

[anonymous]

It’s obvious that there will be cuts in CRM. Senior management has been very quiet but we know better. Here are just a few obvious reasons why CRM will be impacted by the reorg:

1. CRM now called CV. Renal is gone which means we won’t be promoting iptacopan due to be approved in 2023

2. Entresto going generic 7/23 or early 2024

3. The lackluster Leqvio launch

4. Over-bloated sales force and you know who you are

Please feel free to add to the list!

5 pelecarsen a big question mark and even if it were successful, is a very niche market that could never sustain CRM or fill the Leqvio hole with any ounce of significance

 

[anonymous]

It’s obvious that there will be cuts in CRM. Senior management has been very quiet but we know better. Here are just a few obvious reasons why CRM will be impacted by the reorg:

1. CRM now called CV. Renal is gone which means we won’t be promoting iptacopan due to be approved in 2023

2. Entresto going generic 7/23 or early 2024

3. The lackluster Leqvio launch

4. Over-bloated sales force and you know who you are

Please feel free to add to the list!

.... unless we are merging or acquiring or whatever with a company that has a sizeable CV TA or pipeline ...